Lundbeck/Otsuka move lead 5-HT6 Alzheimer's candidate into Phase III
This article was originally published in Scrip
Executive Summary
Building on positive Phase II data released earlier this year, originator Lundbeck and partner Otsuka Pharmaceutical are taking their novel oral 5-HT6 receptor antagonist Lu AE58054 into a large-scale Phase III program for Alzheimer's disease.